The Department of Molecular Oncology, University Medical Center Göttingen is looking as of 1st September 2022, for a

Post-Doctoral Fellow (f/m/d)

limited for 2 years, full-time (38.5 h/week) or part-time | salary according to TV-L

The University Medical Center Göttingen is a tertiary care center and offers great development potential. Its 7,900 employees work in over 65 departments and facilities to provide top-quality patient care, excellent research and modern teaching. Göttingen, “City of Science”, located near the center of Germany, the University Medical Center Göttingen is embedded in the city’s attractive network of scientific research facilities. About us
Our research group within the Department of Molecular Oncology is applying cancer therapeutics as well as antibodies for the treatment of virus infections, in particular to interfere with the replication of SARS- CoV-2. We are now seeking a strong candidate to further evaluate these approaches and to identify druggable steps in the virus replication cycle. Selected References:
Stegmann KM, Dickmanns A, Heinen N, Blaurock C, Karrasch T, Breithaupt A, Klopfleisch R, Uhlig N, Eberlein V, Issmail L, Herrmann ST, SchreieckA, Peelen E, Kohlhof H, Sadeghi B, Riek A, Speakman JR, Groß U, Görlich D, Vitt D, Müller T, Grunwald T, Pfaender S, Balkema-Buschmann A, and Dobbelstein M. (2022) Inhibitors of dihydroorotate dehydrogenase cooperate with Molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication. iScience 10.1016/j.isci.2022.104293 Güttler T, Aksu M, Dickmanns A, Stegmann KM, Gregor K, Rees R, Taxer W, Rymarenko O, Schünemann J, Dienemann C, Gunkel P, Mussil B, Krull J, Teichmann U, Groß U, Cordes VC, Dobbelstein M*, Görlich D*. (2021) Neutralization of SARSCoV- 2 by highly potent, hyperthermostable, and mutation- tolerant nanobodies. EMBO J. 40(19):e107985. doi: 10.15252/embj.2021107985. *co-corresponding authors Stegmann KM, Dickmanns A, Gerber S, Nikolova V, Klemke L, Manzini V, Schlösser D, Bierwirth C, Freund J, Sitte M, Lugert R, Salinas G, Görlich D, Wollnik B, Groß U and Dobbelstein M. (2021) The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models. Virus Research 302, 198469 Your Qualifications:
The successful candidate will hold a PhD degree with a strong background in virology, or alternatively in cell biology and related subjects. Experience in cell culture techniques, molecular biology, microscopy and sequence analysis would be desirable. The ideal candidate is proficient in virus research, but we do consider committed candidates from outside this field. We offer:

• Research projects funded by the Coronavirus Research Network Niedersachsen (COFONI) and by the Volkswagenstiftung, providing an active and collaborative network of researchers
• A friendly, supportive and skilled team
• Proper guidance in shaping your research project
• An extensive range of research training courses
• Opportunities of presenting your science on international meetings
• Salary according to the collective agreement for the public State service (TV-L) including social benefits

The University Medical Center Göttingen is committed to professional equality. We therefore seek to increase the proportion of under-represented genders. Applicants with disabilities and equal qualifications will be given preferential treatment. We look forward to receiving your application by July 15th, 2022: University Medical Center Göttingen
Department of Molecular Oncology
Prof. Dr. Matthias Dobbelstein
Director
Justus-von-Liebig-Weg 11
D-37077 Göttingen
Phone: +49 551/39-60757
E-Mail: mdobbel@uni-goettingen.de Please send your applications exclusively to:
Frau Heike Voigt
Phone: +49 551/39-60763
E-Mail: heike.voigt@med.uni-goettingen.de